# Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

Source: https://onco.cc/trials/nct05362409/  
OnCo record `nct05362409` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of PoMA sonodynamic therapy run by Alpheus Medical, Inc., completed.

## Summary

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma is a phase 1 interventional study registered as NCT05362409 by Alpheus Medical, Inc., with 22 participants enrolled, started 2022-06-29, primary completion reached 2024-12-03. Conditions recorded: High Grade Glioma. Interventions recorded: 5 Aminolevulinic Acid, CV01-delivered ultrasound.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05362409
- Phase: 1
- Setting: A Phase 1 Multi-center Clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy(SDT) in Patients With Recurrent High Grade Glioma (HGG)
- Sponsor: Alpheus Medical, Inc.
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT05362409: https://clinicaltrials.gov/study/NCT05362409

## Connected records

- drugs: [PoMA sonodynamic therapy](https://onco.cc/drugs/poma-sonodynamic-therapy/)
- companies: [Alpheus Medical](https://onco.cc/companies/alpheus-medical/)

---
JSON: https://onco.cc/api/v1/entities/nct05362409.json